FDA Approves Tablet Form of Zanubrutinib for All Approved Indicationsbiopharmadive·10 hours agoBGNE0.00%06160-1.97%
U.S.-Listed Chinese Stocks Mostly Fall Overnight, Baidu Drops 6.96%CoinLive·19 hours agoZH-1.06%JD-2.46%
UBS: Most China Biotech Firms' 1H26 Sales Beat Expectations; Global R&D Catalysts Key in 2H26, BeOne Medicines PreferredAASTOCKS News·Sep 4 at 05:50 AM01877-1.23%01801-2.00%
RemeGen Deploys Idle Funds Into Discloseable Wealth Management ProductsTip Ranks·Sep 2 at 11:43 AM09995-0.96%688331-4.09%
RemeGen authorizes up to RMB 2.5 billion in self-owned funds for wealth management productsPUBT·Sep 2 at 11:09 AM09995-0.96%688331-4.09%
US Forges Drug Pricing Deals With 9 Drugmakers Incl. BEONE MEDICINESAASTOCKS News·Sep 1 at 01:30 AMTEVA+0.24%ALPMY-1.77%
U.S. President Donald Trump Administration Reaches Drug Pricing Deals With Nine Biotech and Pharma FirmsCoinLive·Aug 31 at 10:36 PMBGNE0.00%06160-1.97%
STOCKS | InnoCare Bio-B Falls More Than 10% Before Narrowing LossesCoinLive·Aug 31 at 02:27 AMBGNE0.00%WXXWY-3.63%
STOCKS | WuXi Biologics, BeiGene Fall On Unusual TradingCoinLive·Aug 31 at 01:26 AMBGNE0.00%WXXWY-3.63%
Junshi Biosciences Discloses Planned Stake Reduction by Key A-Share InvestorTip Ranks·Aug 31 at 12:07 AM01877-1.23%688180-2.00%
Junshi Biosciences terminates 2026 A-share employee stock ownership schemePUBT·Aug 26 at 10:33 AM01877-1.23%688180-2.00%
BEONE MEDICINES Interim Net Profit Up 385.8% to USD464M; ADR Gains 0.7% PremarketAASTOCKS News·Aug 26 at 10:25 AMBGNE0.00%06160-1.97%
Citi Raises REMEGEN TP to HKD127.7, Maintains Buy/High Risk RatingAASTOCKS News·Aug 26 at 08:01 AM09995-0.96%688331-4.09%
Daiwa Slightly Raises REMEGEN TP to HKD108, Sees Multiple Catalysts in Next 12 MonthsAASTOCKS News·Aug 26 at 08:01 AM09995-0.96%688331-4.09%
